[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":641},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,188,0,25,[9,60,85,121,144,167,195,223,256,280,308,331,355,381,408,431,450,473,492,508,526,548,568,596,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100053446","phase-4-intravenous-dexamethasone-with-single-shot-versus-continuous-brachial-plexus-block-for-rebound-pain-after-shoulder-surgery-100053446",false,"NCT07699744","Intravenous Dexamethasone With Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain After Shoulder Surgery","Pain Management Protocol Optimization for Rebound Pain Prevention and Enhanced Recovery After Shoulder Surgery: A Randomized Noninferiority Trial of Intravenous Dexamethasone Combined With Single-Shot Versus Continuous Brachial Plexus Block","Inclusion Criteria:\n\n* Adult patients aged 19 to 79 years scheduled for elective shoulder surgery under brachial plexus block and monitored anesthesia care (MAC)\n\nExclusion Criteria:\n\n* Pre-existing neurological deficit of the brachial plexus\n* Emergency surgery\n* American Society of Anesthesiologists (ASA) physical status classification IV or higher\n* Contraindication or history of hypersensitivity to local anesthetics or dexamethasone\n* Severe pulmonary disease (e.g., chronic obstructive pulmonary disease)\n* Body mass index (BMI) ≥ 35 kg\u002Fm²\n* Long-term use of steroids\n* Long-term use of analgesics\n* Inability to cooperate or communicate\n* Pregnancy","ALL","19 Years","79 Years",{"count":21,"type":22},92,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Shoulder surgery often causes severe pain after the operation. To control this pain, doctors commonly perform a nerve block (interscalene brachial plexus block), which numbs the shoulder area. However, when the effect of a single-injection nerve block wears off, many patients experience sudden, intense pain known as \"rebound pain\".\n\nOne way to prevent rebound pain is to place a thin catheter near the nerves so that local anesthetic can be given continuously for a longer period (continuous nerve block). However, this method is technically demanding and can cause problems such as catheter dislodgement, infection, and inconvenience for patients. Another simpler option is to give a single-injection nerve block together with an intravenous (IV) injection of dexamethasone, a steroid medication known to prolong the effect of nerve blocks and reduce rebound pain.\n\nThe purpose of this study is to determine whether a single-injection nerve block combined with IV dexamethasone (5 mg) is not inferior to a continuous nerve block in preventing rebound pain after shoulder surgery. A total of 92 adult patients scheduled for elective shoulder surgery will be randomly assigned to one of the two groups. The main outcome is the rebound pain score, defined as the difference between the last pain score recorded in the recovery room (while the nerve block is still working) and the highest pain score reported within the first 24 hours after the nerve block. The investigators expect that the simpler single-injection method with IV dexamethasone will provide comparable pain control while avoiding the complications and inconvenience of catheter-based continuous nerve blocks.",[28,29,30,31],"Pain, Postoperative","Rebound Pain","Shoulder Injuries","Rotator Cuff Injuries",[33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Rebound pain","Interscalene brachial plexus block","Single-shot nerve block","Continuous peripheral nerve block","Perineural catheter","Dexamethasone","Intravenous dexamethasone","Shoulder surgery","Rotator cuff repair","Regional anesthesia","Postoperative analgesia","Multimodal analgesia","Non-inferiority trial","Enhanced recovery after surgery","NOT_YET_RECRUITING","2026-07-09",{"date":50,"type":51},"2026-07-13","ACTUAL",{"date":53,"type":22},"2026-07-15",{"date":55,"type":22},"2027-07-15",{"name":57,"class":58},"Seoul National University Hospital","OTHER",1,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":59},"100644876","phase-4-efficacy-and-safety-of-eleveld-pkpd-model-based-dosing-during-general-anesthesia-100644876","NCT07675850","Efficacy and Safety of Eleveld PK\u002FPD Model-based Dosing During General Anesthesia","Comparison of Efficacy and Safety Between Eleveld PK\u002FPD Model-based Dosing and Standard Dosing During General Anesthesia","Inclusion Criteria:\n\n* Patients aged 19 to 79 years undergoing elective non-cardiac surgery expected to last 60 minutes or longer under general anesthesia with endotracheal intubation\n\nExclusion Criteria:\n\n* Emergency surgery\n* Surgery requiring evoked potential (EP) monitoring\n* Chronic benzodiazepine users\n* Body Mass Index (BMI) ≥ 35 kg\u002F㎡\n* Chronic kidney disease\n* Hepatic dysfunction or chronic liver disease\n* Contraindication or history of hypersensitivity to remimazolam\n* American Society of Anesthesiologists (ASA) physical status ≥ IV\n* Pregnant women\n* Contraindication or history of hypersensitivity to flumazenil",{"count":68,"type":22},68,[25],"The goal of this randomized, controlled clinical trial is to evaluate the efficacy, safety, and recovery profile of an individualized, Eleveld pharmacokinetic\u002Fpharmacodynamic model-guided dosing strategy for remimazolam in adult patients undergoing elective non-cardiac surgery under general anesthesia.\n\nThe main questions it aims to answer are:\n\nDoes Eleveld model-guided customized dosing significantly reduce the eye-opening time at the end of surgery compared to standard weight-based dosing?\n\nCan the Eleveld model-guided approach prevent relative drug accumulation and delayed emergence while maintaining an adequate depth of anesthesia and comparable hemodynamic stability?\n\nResearchers will compare the Experimental Group (Eleveld model-guided dosing) to the Control Group (Standard weight-based label dosing) to see if preemptive dose optimization based on individual patient covariates effectively reduces the total drug consumption, frequency of rescue flumazenil administration, and emergence time.\n\nParticipants will:\n\n* Be randomly assigned to receive remimazolam for the induction and maintenance of general anesthesia according to either the Eleveld model-guided customized regimen or the standard weight-based regimen.\n* Have their depth of anesthesia continuously monitored using a Bispectral Index (BIS) sensor.\n* Be assessed for the primary outcome (time to eye-opening upon verbal command after discontinuation of anesthetics) and secondary outcomes, including total drug consumption, hemodynamic stability, and postoperative complications (e.g., re-sedation, delirium, PONV).",[72,73],"Remimazolam","Pharmacokinetics and Pharmacodynamics",[72,75,76],"general anesthesia","pharmacokinetics and pharmacodynamics","2026-06-23",{"date":79,"type":51},"2026-06-30",{"date":81,"type":22},"2026-07-30",{"date":83,"type":22},"2027-05-31",{"name":57,"class":58},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100644919","phase-3-a-6-month-mdr-end-plus-regimen-for-rifampicin-resistant-tuberculosis-100644919","NCT07675954","A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis","A Phase 3, Open-Label, Randomised Controlled Trial to Evaluate a 6-Month \"MDR-END Plus\" Regimen (Bedaquiline, Delamanid, Delpazolid, Levofloxacin and Pyrazinamide) Versus the South African Standard of Care Treatment for Rifampicin-Resistant Tuberculosis","MDR-ENDPlus","Inclusion Criteria:\n\n1. Willing and able to voluntarily provide written informed consent to participate in the study prior to initiation of any study-related procedures. For participants under the age of 18 years, signed consent may be obtained from the child's biological parent, legal guardian, or primary caregiver in the presence of the child. Minor participants must also be willing to provide written assent for study participation.\n2. To the best of their knowledge and abilities at screening, participants must be willing and able to adhere to the complete follow-up schedule and all study procedures.\n3. Male or female participants aged 15 years or older.\n4. Participant requires treatment for pulmonary rifampicin-resistant tuberculosis based on one or more of the following:\n\n   * Documented molecular drug susceptibility testing, such as TB nucleic acid amplification test, line probe assay, targeted next-generation sequencing, or culture-based phenotypic drug susceptibility testing on a sample obtained from the participant within 8 weeks prior to screening, even if rifampicin resistance is not re-confirmed on a sample obtained at screening; or\n   * Documented or self-reported clinical symptoms or signs of pulmonary tuberculosis disease, with or without radiological changes consistent with pulmonary tuberculosis, and evidence of close contact with someone with confirmed rifampicin-resistant tuberculosis which, in the opinion of the site investigator, indicates significant exposure and a clinical decision has been made to treat the participant for rifampicin-resistant tuberculosis in routine care; or\n   * Documented peripheral tuberculosis lymphadenitis or tuberculosis pleurisy with confirmed rifampicin-resistant Mycobacterium tuberculosis on lymph node biopsy or pleural fluid aspiration, along with documented symptoms or signs suggestive of pulmonary tuberculosis without culture confirmation.\n5. Not yet started rifampicin-resistant tuberculosis treatment, or initiated rifampicin-resistant tuberculosis treatment in routine care within 10 days prior to enrolment.\n6. Body weight of at least 30 kg.\n7. Documented HIV status and\u002For willing to undergo HIV testing.\n8. Participants living with HIV must be on antiretroviral therapy, or due to start antiretroviral therapy within 2 months of enrolment, regardless of CD4 count, provided they are clinically stable in the opinion of the site investigator.\n9. Pregnant women in any trimester and breastfeeding women are eligible for inclusion.\n\nExclusion Criteria:\n\n1. Two or more of the following four drug groups cannot be used: bedaquiline or clofazimine; delamanid or pretomanid; linezolid or delpazolid; levofloxacin or moxifloxacin, due to any of the following:\n\n   * Documented Mycobacterium tuberculosis resistance in the current or prior treatment episode;\n   * Prior exposure of 1 month or longer, unless protocol-defined exceptions are met;\n   * Absolute contraindications to the relevant study drugs;\n   * Use of prohibited concomitant medications within 14 days prior to enrolment.\n2. Ongoing treatment for rifampicin-resistant tuberculosis for more than 10 days in the current tuberculosis episode.\n3. Isolated extrapulmonary tuberculosis without pulmonary involvement.\n4. Extrapulmonary tuberculosis, with or without concurrent pulmonary tuberculosis, involving the central nervous system, osteoarticular sites, pericardium, or disseminated\u002Fmiliary disease.\n5. Any of the following laboratory or ECG abnormalities:\n\n   A. Alanine transaminase or aspartate transaminase \\>120 U\u002FL; B. Total bilirubin \\>2.4 mg\u002FdL; C. Estimated glomerular filtration rate by the CKD-EPI equation \\\u003C30 mL\u002Fmin\u002F1.73 m²; D. Serum potassium \\\u003C3.2 mmol\u002FL; E. QTcF \\>480 msec.\n6. Atrioventricular block, second or third degree; current or previous history of clinically significant ventricular arrhythmias or long QT syndrome; or family history of long QT syndrome or sudden cardiac death.\n7. Any condition or circumstance which, in the opinion of the investigator, based on information available at the time of screening, raises concerns regarding the participant's safety or ability to participate in the trial or the integrity of the study data.","15 Years",{"count":95,"type":22},294,[97],"PHASE3","This is a phase 3, open-label, randomized clinical trial in adults and adolescents aged 15 years or older who need treatment for rifampicin-resistant tuberculosis in South Africa.\n\nThe goal of this clinical trial is to learn whether a 6-month MDR-END Plus regimen works as well as current standard of care (SoC) treatment for rifampicin-resistant tuberculosis. The trial will also learn whether the MDR-END Plus regimen is safer and easier to tolerate than SoC regimens.\n\nThe main questions this trial aims to answer are:\n\n* Does the MDR-END Plus regimen lead to a favorable treatment outcome 12 months after treatment is stopped, compared with SoC regimens?\n* Do participants receiving the MDR-END Plus regimen have fewer important safety or tolerability problems during treatment and up to 90 days after treatment is stopped, compared with SoC regimens?\n\nResearchers will compare the MDR-END Plus regimen with South African standard of care (SoC) treatment for rifampicin-resistant tuberculosis.\n\nParticipants will:\n\n* Be randomly assigned to receive either the MDR-END Plus regimen or SoC treatment.\n* Take tuberculosis medicines for about 6 months, although treatment may be extended in some cases.\n* Attend study visits during treatment and after treatment is stopped.\n* Have clinical assessments, blood tests, heart tracing tests, vision and nerve assessments, and tuberculosis tests.\n* Be followed for 12 months after treatment is stopped.",[100],"Rifampicin-Resistant Tuberculosis",[102,103,104,105,106,107,108,109,110,111,112,113],"Rifampicin-resistant tuberculosis","Multidrug-resistant tuberculosis","MDR-TB","RR-TB","Bedaquiline","Delamanid","Delpazolid","Levofloxacin","Pyrazinamide","MDR-END Plus","Short treatment regimen","South Africa",{"date":79,"type":51},{"date":116,"type":22},"2026-10-01",{"date":118,"type":22},"2032-06",{"name":57,"class":58},2,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":59},"100622557","perioperative-continuous-glucose-monitoring-accuracy-in-cardiac-surgery-100622557","NCT07385170","Perioperative Continuous Glucose Monitoring Accuracy in Cardiac Surgery","Evaluation of Perioperative Continuous Glucose Monitoring Accuracy in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Patients aged 19 years or older scheduled for cardiac surgery\n\nExclusion Criteria:\n\n* Skin disease at the sensor application site (proximal arm)",{"count":129,"type":22},100,"OBSERVATIONAL","The goal of this clinical trial is to evaluate accuracy of continuous glucose monitoring device called 'Dexcom G7' in patients undergoing cardiac surgery.",[133],"Cardiac Surgery",[135],"continuous glucose monitoring","RECRUITING",{"date":138,"type":51},"2026-06-26",{"date":140,"type":51},"2026-05-27",{"date":142,"type":22},"2028-05-31",{"name":57,"class":58},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100624542","phase-4-hydroxyethyl-starch-versus-crystalloid-and-postoperative-major-adverse-kidney-complications-100624542","NCT07410988","Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications","Effect of 130\u002F0.4 Hydroxyethyl Starch vs. Balanced Crystalloid for Intraoperative Fluid Therapy on Major Composite Renal Outcomes After Cardiac Surgery: a Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 19 years or older scheduled for coronary artery bypass grafting (CABG), heart valve surgery, and\u002For thoracic aortic surgery\n\nExclusion Criteria:\n\n1. Emergency surgery;\n2. Planned implantation of a durable left ventricular assist device;\n3. History of starch allergy or hypersensitivity;\n4. History of kidney transplantation;\n5. Preoperative end-stage renal disease (ESRD) or requirement for renal replacement therapy (RRT);\n6. Preoperative glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2;\n7. Planned intraoperative and postoperative RRT;\n8. Preoperative use of mechanical circulatory support devices (e.g., intra-aortic balloon pump, extracorporeal membrane oxygenation, etc.);\n9. Significant clinical coagulopathy (e.g., active bleeding disorder or thrombocytopenia with a platelet count \\\u003C100,000\u002FµL);\n10. Active infective endocarditis.",{"count":152,"type":22},1292,[25],"This trial aims to compare two intraoperative fluids, namely hydroxyethyl starch (HES) and balanced crystalloids in terms of major adverse kidney events after cardiac surgery. Indications for the study fluids administarion include preload augmentation and intravascular volume replacement during cardiac surgery.",[133],[157],"hydroxyethyl starch","2026-06-21",{"date":160,"type":51},"2026-06-24",{"date":162,"type":51},"2026-06-22",{"date":164,"type":22},"2029-07-31",{"name":57,"class":58},4,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":194,"locationsCount":4},"100641802","patient-controlled-remimazolam-sedation-under-spinal-anesthesia-100641802","NCT07661810","Patient-controlled Remimazolam Sedation Under Spinal Anesthesia","Patient-controlled Remimazolam Sedation During Primary Hip Arthroplasty Under Spinal Anesthesia: an Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 19 to 70 years with an ASA (American Society of Anesthesiologists) physical status of I or II who are undergoing primary hip arthroplasty under spinal anesthesia.\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patients with contraindications to spinal anesthesia\n* Patients who do not consent to intraoperative sedation\n* Patients with contraindications to remimazolam\n* Patients with a history of allergy or hypersensitivity to remimazolam\n* Patients with a baseline MOAA\u002FS (Modified Observer's Assessment of Alertness\u002FSedation) score of 4 or lower\n* Pregnant women","70 Years",{"count":176,"type":22},104,[178],"NA","The goal of this clinical trial is to compare the efficacy of patient-controlled sedation (PCS) versus clinician-controlled sedation (CCS) using remimazolam in adult patients undergoing primary hip arthroplasty under spinal anesthesia.\n\nThe main questions it aims to answer are:\n\n* Does patient-controlled sedation significantly reduce the total consumption of remimazolam compared to clinician-controlled sedation?\n* Are there differences in secondary outcomes, such as sedation depth , sedation-related adverse events, frequency of airway interventions, and patient\u002Fsurgeon satisfaction?\n\nResearchers will compare the PCS group to the CCS group to see if the patient-controlled method leads to a reduction in total remimazolam consumption while maintaining effective sedation.\n\nParticipants will:\n\n* Be randomly assigned to either the PCS group or the CCS group.\n* In the PCS group: Receive an initial 0.05 mg\u002Fkg remimazolam dose over 1 minute. If deeper sedation is desired, the patient can self-administer a 1 mg bolus of remimazolam via a button press, which has a 1-minute lockout interval.\n* In the CCS group: Receive an initial 0.05 mg\u002Fkg remimazolam dose over 1 minute, followed by a continuous infusion starting at 0.3 mg\u002Fkg\u002Fh. The clinician will assess the MOAA\u002FS score every 10 minutes and adjust the infusion rate to maintain a target MOAA\u002FS score of 3.",[181,182,72,183],"Hip Arthroplasty","Spinal Anesthesia","Patient-controlled Sedation",[185,186,187,188],"patient-controlled sedation","remimazolam","spinal anesthesia","hip arthroplasty","2026-06-16",{"date":162,"type":51},{"date":192,"type":22},"2026-07-01",{"date":83,"type":22},{"name":57,"class":58},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100642022","comparison-of-the-incidence-of-major-cardiovascular-events-between-the-combination-of-percutaneous-intervention-and-optimal-drug-therapy-and-the-optimal-drug-therapy-alone-in-patients-with-chronic-coronary-syndrome-100642022","NCT07577518","Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome","Percutaneous Intervention Versus Optimal Medical Therapy in Chronic Coronary Syndrome (PIVOT) Trial","PIVOT","Inclusion Criteria:\n\n* Patients aged 40 years or older\n* Patients suspected of having chronic coronary syndrome who have undergone coronary angiography and confirmed stenotic lesions\n* Patients with lesions suitable for stent insertion who have 50% or more visually estimated stenosis in major coronary arteries with a diameter of 2.5 mm or greater observed on coronary angiography, and who satisfy one or more of the following conditions:\n\n  1. Patients with stenosis of 70% or more confirmed via Quantitative coronary angiography (50% or more for the left main coronary artery)\n  2. Minimum lumen area (MLA) ≤ 4 mm² or plaque burden \\>70% on intravascular ultrasound (IVUS)\n  3. MLA \\\u003C3.5 mm² or area stenosis (AS) \\>65% on Optical Coherence Tomography (OCT)\n  4. The corresponding stenosis on localizing stress imaging using SPECT or PET When there is a significant focal ischemic deficit in the coronary artery region of the lesion and the total perfusion deficit (TPD) is ≥10%\n  5. Pressure wire-based fractional flow reserve (FFR) ≤0.80\n* Patients who can verbally confirm their understanding of invasive physiological or imaging evaluations and the benefits, harms, and alternative treatments of coronary angioplasty using drug-eluting stents, and for whom the patient or their legal representative can submit a written consent form.\n\nAdditional Criteria for nested RCT Studies\n\n* When heart rate control is deemed therapeutically important due to an accompanying increase in heart rate at rest or during symptomatic episodes.\n* When the use of beta-blockers is deemed clinically advantageous due to a history of myocardial infarction.\n* When beta-blockers can help control blood pressure and symptoms in cases of concomitant hypertension.\n* When there is a clinical situation requiring associated tachyarrhythmia or heart rate control.\n* When beta-blockers are deemed more appropriate due to a history of contraindications, intolerance, or side effects of calcium channel blockers.\n\nExclusion Criteria:\n\n* Patients with Left Ventricular Ejection Fraction (LVEF) less than 35%\n* Patients with cardiogenic shock\n* Patients with pulmonary edema or heart failure unresponsive to standard treatment\n* Patients with unstable angina whose symptoms persist despite maximal drug therapy\n* Patients with a history of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina within the last 6 months\n* Patients with active bleeding\n* Patients with major bleeding of the gastrointestinal or urinary system within the last 3 months\n* Patients with coagulation disorders prone to bleeding (including heparin-induced thrombocytopenia)\n* Patients with hypersensitivity to or contraindications to the following drugs: Heparin, Aspirin, Clopidogrel, Prasugrel, Contrast media (Patients sensitive to contrast media are not excluded if the condition can be effectively prevented through pretreatment with steroids or diphenhydramine (e.g., flare-ups).\n* Patients for whom percutaneous coronary intervention (PCI) is contraindicated\n* Patients who have already undergone coronary artery bypass grafting (CABG)\n* Patients with in-stent restenosis in the target lesion\n* Patients with chronic total occlusion (CTO) in major coronary arteries\n* Patients with lesions having an FFR of less than 0.64\n* Patients with coronary arteries that are anatomically unsuitable for both PCI and CABG\n* Patients with non-ischemic dilated cardiomyopathy or hypertrophic cardiomyopathy\n* Patients with severe valvular disease or those judged by the investigator to be likely to require valve surgery or percutaneous valve replacement during the study period\n* Patients with non-cardiac diseases, etc., with a life expectancy of less than one year or expected to have low treatment adherence (at the investigator's judgment)\n* Pregnant or breastfeeding patients\n* Other patients deemed by the investigator to be unsuitable for participation in the clinical trial\n\nAdditional Criteria for nested RCT Studies\n\n* Significant bradycardia at rest, second-degree or higher atrioventricular block, or significant conduction disturbance\n* Bronchial asthma or clinically significant bronchospasmodic disease\n* Symptomatic hypotension\n* Variant angina as a main presentation\n* Other cases where the supervising investigator deems the use of beta-blockers medically inappropriate","40 Years",{"count":205,"type":22},2301,[178],"Comparison of the incidence of major cardiovascular events between the combination of percutaneous intervention and optimal drug therapy and the optimal drug therapy alone in patients with chronic coronary syndrome.\n\n* Main RCT (Randomized Clinical Trial): Patients with chronic coronary syndrome enrolled in the study will be randomized in a 1:1 ratio to either 1) PCI(Percutaneous Coronary Intervention) plus optimal medical therapy or 2) optimal medical therapy alone, with clinical outcomes assessed during follow-up. (2,301 participants)\n* Nested RCT: An embedded randomized supplementary study was conducted on a subset (220 participants) of the total subjects.\n\nIn patients who have decided to use beta-blockers for the control of angina, additional 1:1 randomization evaluates the efficacy of carvedilol sustained-release (SR) and immediate-release (IR) formulations. Both formulations are targeted for use up to the maximal tolerated dose, taking into account patient symptoms.",[209],"Chronic Coronary Syndrome",[211,212,213],"chronic coronary syndrome","percutaneous coronary intervention","optimal medical therapy","2026-06-10",{"date":216,"type":51},"2026-06-12",{"date":218,"type":22},"2026-06-15",{"date":220,"type":22},"2034-03-10",{"name":57,"class":58},20,{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},"100643420","naltrexone-for-nonsuicidal-self-injury-100643420","NCT07641283","Naltrexone for Nonsuicidal Self-Injury","A Randomized, Double-Blinded Clinical Trial to Evaluate the Effectiveness of Naltrexone in Improving Nonsuicidal Self-Injurious Behavior","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Individuals aged 16 years or older.\n  2. Individuals with clinically significant nonsuicidal self-injurious behavior.\n  3. Individuals who are able to understand the study procedures and provide written informed consent. For minors, consent from a legal guardian and assent from the participant will be obtained according to applicable regulations.\n  4. Individuals who are able to comply with study procedures, including clinical visits, medication administration, and study assessments.\n  5. Women of childbearing potential must have a negative urine pregnancy test at screening and agree to use appropriate contraception during the study period.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Current serious suicidal ideation or high suicide risk, as determined by the investigator.\n  2. Current opioid use, opioid dependence, or use of opioid-containing medications.\n  3. Current use of opioid antagonists or medications that may interact with naltrexone, including methadone or buprenorphine.\n  4. Use of naltrexone within 1 week before screening.\n  5. Positive naloxone challenge test or positive urine opioid test, if applicable.\n  6. Known hypersensitivity to naltrexone or any component of the investigational product.\n  7. Active liver disease, active hepatitis, or clinically significant hepatic impairment.\n  8. Clinically significant renal impairment.\n  9. Pregnancy or breastfeeding.\n  10. Intellectual disability, organic brain disorder, or other condition that may interfere with the participant's ability to understand study procedures or complete assessments.\n  11. Inability to read or write Korean sufficiently to complete study assessments.\n  12. Documented prior non-response to naltrexone for nonsuicidal self-injury, as judged by the investigator.\n  13. Any other clinically significant medical or psychiatric condition that, in the opinion of the investigator, would make participation inappropriate or unsafe.","16 Years",{"count":232,"type":22},150,[178],"This randomized, double-blinded, placebo-controlled clinical trial aims to evaluate the efficacy and safety of naltrexone in reducing nonsuicidal self-injurious behavior among individuals with nonsuicidal self-injury. Participants will be randomly assigned to receive either naltrexone plus treatment as usual or placebo plus treatment as usual for 6 weeks.\n\nThe primary objective is to determine whether naltrexone reduces the frequency of nonsuicidal self-injurious behavior compared with placebo. Secondary objectives include evaluating changes in clinical severity, suicidal ideation, self-injury-related urges, ecological momentary assessment measures, and safety outcomes.",[236,237],"Nonsuicidal Self-Injury","Self-Injurious Behavior",[239,240,241,242,243,244,245,246],"Nonsuicidal self-injury","NSSI","Self-injurious behavior","Naltrexone","Opioid antagonist","Impulsivity","Suicidal ideation","Ecological momentary assessment","2026-06-08",{"date":249,"type":51},"2026-06-11",{"date":251,"type":22},"2026-06",{"date":253,"type":22},"2028-06",{"name":57,"class":58},3,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":263,"sex":17,"minAge":264,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":59},"100643497","reduced-vaccine-response-to-hzsu-in-sle-100643497","NCT07636044","Reduced Vaccine Response to HZ\u002Fsu in SLE","Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Males or females ≥ 50 years of age at time of consent\n* ≥ 4 of the 1997 ACR13 or the 2012 SLICC\u002FACR criteria for SLE (14, 15)\n* Clinically stable SLE\n* Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks\n* Corticosteroid use: ≥ 5mg\u002Fday of prednisolone equivalent\n* Antimalarials (≤ 400 mg\u002Fday)\n* Azathioprine (≤ 3 mg\u002Fkg\u002Fday)\n* Mycophenolate mofetil (≤ 3 mg\u002Fday)\n* Tacrolimus (≤ 5mg\u002Fday)\n* Methotrexate (≤ 20mg\u002Fweek)\n* Cyclosphosphamide (≤ 1mg\u002FBSA\u002Fmonth)\n* Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine\n* Must understand and voluntarily sign an informed consent form including writing consent for data protection\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Acute infection with temperature \\>38C at the time of vaccination\n* Previous anaphylactic response to vaccine components or to egg\n* History of Guillain-Barre syndrome or demyelinating syndromes\n* Any condition including laboratory abnormality which places the subject at unacceptable risk\n* Subjects who decline to participate",true,"50 Years",{"count":266,"type":22},80,"The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ\u002Fsu, \"Shingrix\") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.",[269,270,271],"Vaccine Reaction","Zoster","Systemic Lupus Erythematosus","2026-06-04",{"date":274,"type":51},"2026-06-09",{"date":276,"type":51},"2024-10-01",{"date":278,"type":22},"2030-10-01",{"name":57,"class":58},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":255},"100643184","phase-4-branched-chain-amino-acids-for-sarcopenia-in-patients-undergoing-total-knee-arthroplasty-100643184","NCT07634523","Branched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty","The Effect of BCAA on Sarcopenia in Total Knee Arthroplasty Patients: A Multi-center, Randomized Controlled Trial","LIVACT IIT","Inclusion Criteria:\n\n1\\. Patients aged 40 to 100 years who are scheduled to undergo total knee arthroplasty.\n\nExclusion Criteria:\n\n1. Participants who used antiretroviral agents within 4 weeks before the first administration of Livact.\n2. Participants who used medications associated with fatty liver within 4 weeks before the first administration of Livact, including thiazolidinediones, sodium glucose cotransporter 2 inhibitors, amiodarone, methotrexate, tamoxifen, valproate, or corticosteroids.\n3. Participants who used branched chain amino acid products or multinutritional supplements within 4 weeks before the first administration of Livact.\n4. Participants who used pain medications other than those prescribed for total knee arthroplasty treatment within 2 weeks before the first administration of Livact.\n5. Participants with markedly decreased hepatic protein synthetic function.\n6. Participants with congenital branched chain amino acid metabolism disorders.\n7. Participants with hereditary galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption.\n8. Participants with a history of high tibial osteotomy.\n9. Participants with neurologic diseases such as stroke or Parkinson disease.\n10. Participants with gait disturbance due to causes other than arthritis.\n11. Participants taking medication for spinal stenosis.\n12. Participants with a history of hypersensitivity to the investigational product or its components.\n13. Pregnant or breastfeeding participants.\n14. Participants planning pregnancy during the trial or who have the possibility of pregnancy but do not agree to use appropriate contraception during the trial.\n15. Participants judged by the investigator to be inappropriate for participation in the clinical trial.","100 Years",{"count":290,"type":22},140,[25],"This multicenter, prospective, randomized controlled trial evaluates whether postoperative administration of branched chain amino acids affects skeletal muscle mass index and sarcopenia related functional outcomes in patients undergoing total knee arthroplasty.\n\nParticipants are randomly assigned to receive Livact granules 4.15 g three times daily for 3 months after surgery or to receive standard postoperative care without branched chain amino acid administration. Skeletal muscle mass index, physical function, patient reported outcomes, laboratory findings, medication compliance, and adverse events are assessed at baseline, 5 weeks, and 15 weeks after surgery.",[294,295],"Sarcopenia","Total Knee Arthroplasty",[297,298,299,300,301,295,294,302],"Branched Chain Amino Acids","BCAA","Livact","Skeletal Muscle Mass Index","Bioelectrical Impedance Analysis","Randomized Controlled Trial",{"date":274,"type":51},{"date":305,"type":51},"2025-02-06",{"date":83,"type":22},{"name":57,"class":58},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":263,"sex":17,"minAge":316,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100643377","agentic-ai-personalized-dietary-management-study-100643377","NCT07638241","Agentic AI Personalized Dietary Management Study","Effectiveness of an Agentic AI-Based Personalized Dietary Management Algorithm in Health Screening Participants: A Randomized Controlled Trial","AIDiet","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Individuals from the general population who underwent a health examination at the Seoul National University Hospital Healthcare System Gangnam Center\n* Individuals who are capable of independently using a smartphone and operating study-related applications or text messaging functions\n* Individuals without conditions that significantly interfere with standard dietary management, as specified in the exclusion criteria \\[Section 9.2 Exclusion Criteria\\]\n\nExclusion Criteria:\n\n* Individuals unable to use a smartphone or study-related digital program\u002Fapplication, including those without a smartphone or unable to operate text messaging or application-based functions.\n* End-stage renal disease or patients currently receiving dialysis\n* Active cancer or currently undergoing chemotherapy or radiotherapy\n* Severe heart failure, liver cirrhosis, or hepatic insufficiency accompanied by varices, bleeding, ascites, hepatic encephalopathy, or jaundice\n* Malabsorption disorders such as Crohn's disease or short bowel syndrome\n* Poorly controlled hyperthyroidism or hypothyroidism\n* Diagnosed eating disorders or severe psychiatric disorders\n* Pregnant or breastfeeding women, or women who may become pregnant during study participation.\n* Individuals with recent major weight-related interventions or extreme body weight changes within the past 3 months, including:Bariatric surgery such as gastrectomy or gastric bypass surgery Newly initiated anti-obesity pharmacotherapy (e.g., semaglutide\u002FWegovy, tirzepatide\u002FMounjaro)\n* Individuals considered by the investigator to have poor compliance potential or otherwise deemed unsuitable for participation in the clinical study.","20 Years","90 Years",{"count":319,"type":22},200,[178],"This randomized controlled trial aims to evaluate the effectiveness of an Agentic AI-based personalized dietary management algorithm among adults undergoing health screening. Participants will be assigned to a control group, a static goal AI intervention group, or an adaptive goal AI intervention group and followed for 12 weeks.",[323],"Dietary Behavior; Metabolic Health; Obesity; Lifestyle Modification; Metabolic Syndrome Risk",[325],"Agentic AI; Personalized Nutrition; Digital Health; AI Coaching; Precision Nutrition; Dietary Management; Health Screening",{"date":214,"type":51},{"date":247,"type":22},{"date":329,"type":22},"2028-12-31",{"name":57,"class":58},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":316,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":59},"100643493","eoi-block-vs-tap-block-in-minimally-invasive-hepatectomy-100643493","NCT07615231","EOI Block vs. TAP Block in Minimally Invasive Hepatectomy","External Oblique Intercostal Plane Block and Subcostal Transversus Abdominis Plane Block in Minimally Invasive Hepatectomy: Non-inferiority Trial","EOIvsTAP","Inclusion Criteria:\n\nScheduled to undergo elective robotic or laparoscopic minimally invasive hepatectomy\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists physical status IV or higher\n* History of chronic pain or current use of analgesics, antidepressants, or anticonvulsants for pain management\n* Known hypersensitivity to general anesthetics, opioids, or local anesthetics\n* Conversion to open hepatectomy\n* Requirement for mechanical ventilation for more than 2 hours within 48 hours postoperatively\n* Any other clinical condition that makes the patient unsuitable for participation in the study.","80 Years",{"count":290,"type":22},[178],"This study aims to compare the analgesic efficacy of two different ultrasound-guided nerve blocks-the External Oblique Intercostal (EOI) block and the Subcostal Transversus Abdominis Plane (TAP) block-in patients undergoing minimally invasive hepatectomy. All participants will receive standardized general anesthesia and perioperative care at Seoul National University Hospital. Following anesthesia induction, patients will be randomly assigned to receive either an EOI block or a subcostal TAP block with 0.375% ropivacaine to provide regional pain relief. Postoperative pain will be managed using a combination of scheduled non-opioid analgesics and a fentanyl-based patient-controlled analgesia (PCA) device. The primary objective is to evaluate which regional technique more effectively reduces cumulative opioid consumption during the first 24 hours after surgery. Additionally, the study will assess pain intensity using the Numerical Rating Scale (NRS), the incidence of postoperative nausea and vomiting, and the overall recovery profile, including the time to first ambulation.",[344],"Hepatectomy",[346,347,348],"minimally invasive hepatectomy","TAP block","EOI block",{"date":247,"type":51},{"date":351,"type":22},"2026-06-01",{"date":353,"type":22},"2027-06-30",{"name":57,"class":58},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":363,"maxAge":4,"enrollmentInfo":364,"targetDuration":365,"studyType":130,"phases":4,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":59},"100639397","study-on-cutoff-revision-effects-and-evaluation-of-nnt-in-primary-aldosteronism-100639397","NCT07621458","Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism","Impact of the Revised Aldosterone-Renin Ratio (ARR) Cutoff in the 2025 Primary Aldosteronism Guideline in Real-World Practice: A Prospective Study","SCREEN-PA","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of hypertension or current use of antihypertensive medications\n* Plasma renin activity (PRA) ≤1 ng\u002FmL\u002Fhr\n* Plasma aldosterone concentration (PAC) ≥10 ng\u002FdL by immunoassay or ≥7.5 ng\u002FdL by liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS)\n* Aldosterone-to-renin ratio (ARR) \\>20 by immunoassay or \\>15 by LC-MS\u002FMS\n* Participants meeting criteria for intermediate probability of lateralizing primary aldosteronism\n* For participants with ARR values between 20 and 30, repeat ARR measurement within 26 weeks demonstrating persistent ARR \\>20\n\nExclusion Criteria:\n\n* Current use of mineralocorticoid receptor antagonists or amiloride that cannot be discontinued according to study protocol\n* Previous adrenalectomy\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy\n* Current use of combined estrogen- and progesterone-containing oral contraceptive pills or hormone replacement therapy\n* High probability primary aldosteronism defined as hypokalemia with PRA \\\u003C0.2 ng\u002FmL\u002Fhr and PAC \\>20 ng\u002FdL by immunoassay or \\>15 ng\u002FdL by LC-MS\u002FMS\n* Low probability primary aldosteronism defined as PAC \\\u003C11 ng\u002FdL by immunoassay or \\\u003C8 ng\u002FdL by LC-MS\u002FMS\n* Inability to undergo saline infusion test according to investigator judgment","18 Years",{"count":232,"type":22},"1 Year","The goal of this observational study is to evaluate the real-world impact of applying the revised aldosterone-to-renin ratio (ARR) cutoff recommended in the 2025 primary aldosteronism guideline in adults with hypertension and biochemical findings suggestive of an intermediate probability of lateralizing primary aldosteronism (PA). The main questions it aims to answer are:\n\n* What is the number needed to test (NNT) to diagnose one case of primary aldosteronism when using the revised ARR cutoff (\\>20)?\n* What is the optimal ARR cutoff for diagnosing PA in Korean patients?\n* What is the biochemical treatment response rate at 6 months after treatment for confirmed PA?\n\nParticipants will:\n\n* Undergo standardized ARR testing after protocol-based medication adjustment and controlled sampling conditions.\n* Undergo confirmatory testing using the saline infusion test (SIT).\n* Receive standard clinical management for confirmed PA according to institutional practice.\n* Be followed for assessment of biochemical outcomes after treatment.",[368],"Primary Aldosteronism",[368,370,371,372],"Aldosterone-to-Renin Ratio","Number Needed to Test","Screening","2026-05-31",{"date":375,"type":51},"2026-06-02",{"date":377,"type":51},"2026-04-01",{"date":379,"type":22},"2027-12-31",{"name":57,"class":58},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":59},"100515583","pharmacological-reversal-of-neuromuscular-blockade-in-critically-ill-patients-100515583","NCT05993390","Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients","Effect of Neuromuscular Reversal Agents on Time for Neurological Assessment After Endotracheal Intubation in Critically Ill Patients","Inclusion Criteria:\n\n* Adult patients 19 years of age or older who were intubated after admission to the intensive care unit.\n\nExclusion Criteria:\n\n* Patients younger than 19 years of age\n* Patients who are not neurologically evaluable or have concomitant neurologic dysfunction\n* Patients with neuromuscular disorder\n* Patients with a history of drug allergic reactions to sugammadex or neostigmine\n* Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives",{"count":389,"type":22},30,[178],"The goal of this clinical trial is to compare the effect of use of reversal agents for neuromuscular blockade in critically ill patients on time for neurological assessment after endotracheal intubation\n\nThe main questions it aims to answer are:\n\n* The use of reversal agents for neuromuscular blockade after endotracheal intubation may reduce the time for neurological assessment.\n* The types of reversal agents for neuromuscular blockade may affect the time for neurological assessment.\n\nParticipants will receive different reversal agents or no medications based on the assigned groups. Thirty minutes after intubation using rocuronium, medication is administered, and the time of initial confirmation of eye opening and movement is recorded.\n\nResearchers will compare 3 groups (sugammadex, neostigmine and control(no medication) to see the difference of time for neurological assessment after endotracheal intubation.",[393,394,395],"Neuromuscular Blockade","Critical Illness","Neurologic Findings",[397,398,399,400],"Reversal of neuromuscular blockade","Neurologic assessment","Endotracheal intubation","Critically ill patient","2026-05-30",{"date":375,"type":51},{"date":404,"type":51},"2024-01-11",{"date":406,"type":22},"2028-04-30",{"name":57,"class":58},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":264,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":59},"100512323","prevention-of-delirium-in-icu-using-multimodal-interventions-100512323","NCT05950958","Prevention of Delirium in ICU Using Multimodal Interventions","The Impact of Audio and Visual Intervention in Preventing ICU Delirium in Critically Ill Patients : A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adult patients over 50 years who are expected to spend more than 24 hours in the intensive care unit\n\nExclusion Criteria:\n\n* Patients who developed delirium before entering the intensive care unit\n* Patients with cognitive impairment\n* Patients who have hearing or vision deficits, or have difficulty in communication\n* Patients who are expected to die within 24 hours or do not want life-sustaining treatment",{"count":416,"type":22},196,[178],"This study was designed to evaluate the impact of non-pharmacological multimodal interventions including ongoing orientation, sensory correction, setting of familiar circumstance and promotion of sleep enviromnet for prevention of delirium in intensive care unit.",[420],"Intensive Care Unit Delirium",[422,423,424],"Delirium","Intensive Care Unit","Non-pharmacological intervention",{"date":375,"type":51},{"date":427,"type":51},"2022-08-01",{"date":429,"type":22},"2028-07-31",{"name":57,"class":58},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":449,"locationsCount":59},"100563905","phase-2-trial-to-evaluate-the-effects-of-naltrexone-in-nonsuicidal-self-injury-100563905","NCT06622239","Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury","A Randomized, Double-Blinded Clinical Trial to Evaluate the Effects of Naltrexone in Improving Nonsuicidal Self-injurious Behavior","NiNsSIB","Inclusion Criteria:\n\n* Age: 16 years of age or older\n* Clinical interviews meet DSM-5\\'s nonsuicidal self-injury diagnostic criteria\n* Nonsuicidal self-injurious behavior has been observed more than once in the past two months\n* Obsessive Compulsive Drinking Scale general craving item 2 or more points (strong desire)\n* Self-injurious behavior continues even with 4 weeks of general psychiatric treatment for underlying disease\n* Anyone who can independently read and fill out the questionnaire and speak Korean\n* Who understand the written consent and voluntarily agree to participate in the study\n* Female participants of childbearing age must be negative on urine pregnancy test at screening\n\nExclusion Criteria:\n\n* currently in psychotic or manic conditions\n* currently experiencing serious suicidal thoughts\n* history of substance-related disorders including opioid\n* do not agree to use very effective contraception from the time of signing the test subject\\'s consent form to the end of study period (non-fertility women and postmenopausal women excluded from the contraception requirements)\n* Severe medical conditions (angina pectoris, myocardial infarction, arrhythmia, any cancer that is not in remission, hypothyroidism, hyperthyroidism, diabetes, hepatitis B, hepatitis C, epilepsy, dementia, HIV infection)\n* intellectual disability or organic brain damage\n* difficulty reading and writing Korean\n* taking opioid antagonists (methadone, buprenorphine, etc.)\n* on an opiate painkiller\n* currently opiate dependence\n* acute opiate withdrawal symptoms\n* naloxone-induced test is positive or the urine test is positive for opiates\n* have been sensitized to this drug\n* acute hepatitis, liver failure, severe liver failure\n* renal disease\n* hypersensitivity reaction to the main ingredient or other ingredients of this drug\n* a pregnant woman, a woman who may be pregnant, or a lactating woman\n* Since this drug contains lactose, genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc\n* active liver disease",{"count":232,"type":22},[441],"PHASE2","The goal of this clinical trial is to learn if naltrexone works to treat nonsuicidal self-injurious behavior in adolescents and adults.",[236],"2026-05-20",{"date":446,"type":51},"2026-05-22",{"date":351,"type":22},{"date":83,"type":22},{"name":57,"class":58},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":59},"100640397","binaural-sound-during-phacoemulsification-and-posterior-chamber-lens-implantation-in-geriatric-patients-100640397","NCT07609186","Binaural Sound During Phacoemulsification and Posterior Chamber Lens Implantation in Geriatric Patients","Effect of Binaural Sound During Phacoemulsification and Posterior Chamber Lens Implantation on Postoperative Patient Satisfaction in Geriatric Patients: a Single-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo their first phacoemulsification and posterior chamber intraocular lens implantation (PE \\& PCL) under monitored anesthesia care (MAC).\n* Patients aged 65 years or older.\n* Patients who fully understand the study and voluntarily provide written informed consent to participate.\n\nExclusion Criteria:\n\n* Patients undergoing their second consecutive PE \\& PCL surgery.\n* Patients with hearing loss, hearing impairment, or those who use hearing aids.\n* Patients unable to wear earphones due to diseases of the external auditory canal.\n* Patients who chronically use hypnotics or sedatives.\n* Patients with a history of obstructive sleep apnea or a Body Mass Index of 35 kg\u002Fm² or higher.\n* Patients with a history of alcohol or drug dependence.\n* Patients with a history of epilepsy or seizure disorders.\n* Patients who are unable to complete a written questionnaire.\n* Patients deemed unsuitable for participation in the clinical trial based on the investigator's clinical judgment.","65 Years",{"count":459,"type":22},60,[178],"The purpose of this study is to evaluate the effects of binaural beats on patient satisfaction and intraoperative comfort in patients aged 65 years or older undergoing cataract surgery (phacoemulsification and posterior chamber intraocular lens implantation) under monitored anesthesia care (MAC) with propofol.\n\nParticipants are randomly assigned to either a binaural beat group or a control group. The binaural beat group will wear earphones and listen to binaural beats from the time they arrive at the operating room until the surgery is completed. The control group will wear identical earphones but will not receive any auditory stimulus.\n\nDuring the procedure, standard vital signs and the bispectral index (BIS) will be continuously monitored in both groups. Following the surgery, the investigators will assess the patients' overall satisfaction using a 7-point Likert scale. Secondary assessments include patient preference for the anesthesia method, intraoperative pain intensity, sedation level, anxiety level, and quality of life (EQ-VAS) measured by a visual analogue scale. Any surgery-related discomfort or adverse events will also be recorded and compared between the two groups.",[463,464,465],"Cataract","Binaural Beats","Geriatric Anesthesia","2026-05-19",{"date":140,"type":51},{"date":469,"type":51},"2025-08-07",{"date":471,"type":22},"2026-07-08",{"name":57,"class":58},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":59},"100621750","long-term-follow-up-study-to-evaluate-long-term-safety-and-efficacy-of-allogenic-umbilical-cord-derived-mesenchymal-stem-cell-in-patients-with-rotator-cuff-disease-100621750","NCT07374679","Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease","A Single Center, Open Label, Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease","Inclusion Criteria:\n\n* Subjects who received the investigational medicinal product in the Phase 1\u002F2a clinical trial (ASB-IP-001).\n* Subjects who voluntarily agreed to participate in this long-term follow-up study and provided written informed consent.\n\nExclusion Criteria:\n\n* Subjects who cannot be contacted by any means, including telephone, mail, or e-mail, and for whom follow-up assessment is therefore not feasible.\n* Subjects deemed inappropriate for participation in this long-term follow-up study at the investigator's discretion, including:\n\n  * Cases in which participation in the study may pose a significant risk to the subject's health or safety; ② Cases in which long-term follow-up visits or assessments are practically impossible due to cognitive impairment, communication difficulties, or similar conditions; ③ Cases in which continued participation in follow-up is unlikely due to difficulty adhering to the study schedule (e.g., prolonged hospitalization, long-term residence abroad).",{"count":481,"type":22},21,"The purpose of this study is to evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients with Rotator Cuff Disease",[484],"Rotator Cuff Disease","2026-05-18",{"date":446,"type":51},{"date":488,"type":51},"2026-01-27",{"date":490,"type":22},"2032-01-30",{"name":57,"class":58},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":59},"100527500","left-bundle-branch-area-pacing-in-heart-failure-patients-with-ejection-fraction-below-normal-100527500","NCT06148571","Left Bundle Branch Area Pacing in Heart Failure Patients With Ejection Fraction Below Normal","Inclusion Criteria:\n\n* Patients previously diagnosed with heart failure with mid-range(or mildly reduced) ejection fraction and heart failure with reduced ejection fraction, which was documented by an appropriate echocardiographic study (Left ventricle ejection fraction \\\u003C50%), and\n* Patients with indications of cardiac pacing or cardiac resynchronization therapy\n\nExclusion Criteria:\n\n* Patients aged less than 19 years.\n* Pregnant.\n* Patients with an expected life expectancy of less than 1 year.\n* Patients with a mechanical valve for the tricuspid valve.\n* Patients who need atrial pacing only.\n* Patients who are not capable of receiving a transvenous pacemaker for any reason.",{"count":319,"type":22},"While cardiac resynchronization therapy remains the mainstay for advanced HF, it is not always feasible due to unfavorable anatomy of coronary sinus or pacing characteristics. In such cases, left bundle branch area pacing itself or left bundle optimized cardiac resynchronization therapy could be a rescue therapy for failed or unsuccessful biventricular cardiac resynchronization therapy. However, the efficacy and safety of left bundle branch area pacing (or left bundle optimized cardiac resynchronization therapy) as rescue therapy for biventricular cardiac resynchronization therapy is largely hypothetic and lack concrete evidence still.\n\nTherefore, there is an unmet need for the registry purposed for left bundle branch area pacing among heart failure with mid-range (or mildly reduced) ejection fraction and heart failure with reduced ejection fraction patients to investigate its efficacy and safety.\n\nThis study aims to investigate the efficacy and safety of left bundle branch area pacing in heart failure patients with ejection fraction below normal using Selectra catheters.",[501],"Left Ventricular Ejection Fraction Less Then or Equal to 50percent",{"date":466,"type":51},{"date":504,"type":51},"2023-10-10",{"date":506,"type":22},"2026-12-31",{"name":57,"class":58},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":59},"100515796","pulmonary-vein-isolation-strategy-of-very-high-power-short-duration-in-patients-with-paroxysmal-atrial-fibrillation-100515796","NCT05996159","Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation","Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation: Q-INDEX Trial","Inclusion Criteria:\n\n* Patients undergoing PVI for PAF\n\nExclusion Criteria:\n\n* Aged less than 19 years\n* Patients with persistent AF\n* Patients with previous ablation or surgery for AF\n* Patients with intracardiac thrombus or thromboembolic events within the previous 90 days\n* Patients with cardiac surgery or acute coronary syndrome within the previous 90 days\n* Patients with contraindication(s) for using oral anticoagulants\n* Patients with LA anteroposterior diameter of more than 55 mm\n* Patients with left ventricular ejection fraction less than 35%\n* Pregnants or those who plan to become pregnant during the study\n* Life expectancy less than a year",{"count":232,"type":22},[178],"This study aims to investigate the effect of reducing ablation time for a hybrid approach of vHPSD and AI-guided ablation using the QDOT Micro catheter in PVI among patients with PAF.",[519],"Paroxysmal Atrial Fibrillation",{"date":444,"type":51},{"date":522,"type":51},"2023-11-07",{"date":524,"type":22},"2027-05-01",{"name":57,"class":58},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":533,"maxAge":363,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":59},"100636957","preliminary-efficacy-of-a-remote-cardiac-rehabilitation-program-in-pediatric-patients-with-complex-congenital-heart-disease-100636957","NCT07572435","Preliminary Efficacy of a Remote Cardiac Rehabilitation Program in Pediatric Patients With Complex Congenital Heart Disease","Preliminary Efficacy of a Community-Based Remote Cardiac Rehabilitation Program on Cardiopulmonary Function and Quality of Life in Pediatric Patients With Complex Congenital Heart Disease: A Single Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 8 to 18 years.\n* Diagnosed with complex congenital heart disease (e.g., single ventricle, transposition of the great arteries) and have a history of cardiac surgery.\n* At least 3 months post-cardiac surgery and maintaining a stable hemodynamic status.\n* Capable of utilizing remote programs (mobile apps, video platforms, etc.) in the home environment with technical support from guardians.\n* Participant or guardian has agreed to participate and signed the written informed consent form.\n* Confirmed to have decreased physical activity level and physical well-being through assessments (Must meet both):\n* KIDSCREEN-27 Parent Proxy-report 'Physical well-being' domain T-score of 40 or below.\n* Exercise Vital Sign (EVS) survey indicating moderate-to-vigorous physical activity (MVPA) time of less than 420 minutes per week.\n\nExclusion Criteria:\n\n* Ongoing cardiovascular diseases such as uncontrolled arrhythmia, acute heart failure, myocarditis, or pericarditis.\n* Neurological or musculoskeletal disorders that make independent exercise impossible.\n* Cognitive impairment that prevents understanding or following the instructions of the remote rehabilitation program.\n* Clinical levels of depression or anxiety restricting exercise participation, as determined by the attending physician (assessed via Korean Children's Depression Inventory 2: Self-Report \\[K-CDI-2:SR\\] and Revised Children's Manifest Anxiety Scale, Second Edition \\[RCMAS-2\\]).\n* Inability to cooperate with study tests, such as the Cardiopulmonary Exercise Test (CPET), Electrocardiogram (ECG), and 6-Minute Walk Test (6MWT).\n* Currently wearing an artificial pacemaker.","8 Years",{"count":535,"type":22},45,[178],"This study aims to evaluate the preliminary efficacy of a 12-week community-based remote cardiac rehabilitation program on cardiopulmonary function and quality of life in pediatric patients (aged 8 to 18 years) with complex congenital heart disease. Participants will be randomly assigned to either an experimental group receiving the remote cardiac rehabilitation program or a control group receiving the standard of care.",[539],"Complex Congenital Heart Disease","2026-05-06",{"date":542,"type":51},"2026-05-07",{"date":544,"type":22},"2026-05-01",{"date":546,"type":22},"2029-12-31",{"name":57,"class":58},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":59},"100577130","phase-1-effects-of-allogenic-umbilical-cord-derived-mesenchymal-stem-cells-on-patients-with-rotator-cuff-disease-100577130","NCT06794294","Effects of Allogenic Umbilical Cord-Derived Mesenchymal Stem Cells on Patients With Rotator Cuff Disease","A Single Center, Open Label, Phase 1\u002F2a Study to Evaluate Safety and Exploratory Efficacy of Allogenic Umbilical Cord Derived Mesenchymal Stem Cell Treatment in Patients With Rotator Cuff Disease","Inclusion Criteria:\n\n* Male or female 19 years of age and older.\n* Patients with unilateral shoulder pain lasting for at least 3months\n* Patients who do not respond to conservative treatment.\n* Patients who have not responded to sufficient non-surgical treatments, including medication, injection therapy, physical therapy, or exercise therapy, for more than 3 months\n* Patients who have a partial-thickness rotator cuff tear confirmed with magnetic resonance imaging (MRI) or ultrasonography (US).\n* Patients without any restrictions on clinical trial procedures, including hospitalization.\n\nExclusion Criteria:\n\n* Patients who have received subacromial injection therapy on the affected shoulder within the past 3 months.\n* Patients who have undergone rotator cuff surgery on the affected shoulder within the past 6 months\n* Patients with a history of receiving stem cell therapy for the shoulder.\n* Patients with the following shoulder conditions: complete rotator cuff tear, adhesive capsulitis, or isolated acromioclavicular joint arthropathy.\n* Patients showing or suspected of having the following radiological findings: malignancy, severe osteoarthritis of the glenohumeral joint, or skeletal abnormalities decreasing the subacromial space.\n* Patients presenting with symptomatic cervical spine disorders.\n* Patients with concurrent bilateral shoulder pain\n* Patients with polyarthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.\n* Patients with neurological deficit\n* Pregnant women or lactating mothers.\n* Patients unwilling to use effective contraception during the clinical trial period.\n* Patients with current HBV, HCV, or HIV infections, or those with a positive RPR test.\n* Patients with severe diseases that may affect the clinical trial, including cardiovascular disease, renal disease, liver disease, endocrine disorders, or malignancies.\n* Patients who are unable to understand the questionnaires used for assessing their clinical status, including the Visual Analogue Scale (VAS), or those with psychiatric disorders impairing communication.\n* Patients who do not wish to participate in the clinical trial or are unable to comply with follow-up schedules.\n* Patients who have participated in another clinical trial within the last 3 months.\n* Patients deemed unsuitable for participation in this clinical trial at the investigator's discretion",{"count":481,"type":22},[557,441],"PHASE1","The purpose of this study is to evaluate safety and efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients with Rotator Cuff Disease",[484],"2026-04-28",{"date":562,"type":51},"2026-04-29",{"date":564,"type":51},"2025-01-17",{"date":566,"type":22},"2027-01",{"name":57,"class":58},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":59},"100532742","pill-in-the-pocket-oral-anticoagulation-strategy-after-af-catheter-ablation-100532742","NCT06216769","Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation","Comparison Between Continuous Oral Anticoagulation Versus Pill-in-the-POCKET Oral AntiCoagulation Strategy Guided by Continuous Rhythm Monitoring Using Implantable Loop Recorder After Atrial Fibrillation Catheter Ablation","POCKET-OAC","Inclusion Criteria:\n\n1. Patients who are scheduled to undergo atrial fibrillation catheter ablation due to atrial fibrillation refractory to antiarrhythmic drug treatment.\n2. Patients with non-gender CHA2DS2-VASc score 1-4.\n3. Patients who are taking direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) and further plan taking them life-long to prevent stroke caused by atrial fibrillation.\n4. Patients aged 19-89 (inclusive) who voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with a stroke\u002Ftransient ischemic attack history.\n2. Patients with underlying diseases and bleeding findings contraindicated to anticoagulation (e.g., coagulation disorders, bleeding conditions, significant gastrointestinal bleeding within 6 months of enrollment, history of intracranial\u002Fintraocular\u002Fnontraumatic bleeding, thrombolysis within 48 hours of study enrollment).\n3. Patients who are contraindicated to anticoagulants other than those listed above.\n4. Patients who are hemodynamically unstable at the time of study enrollment: cardiogenic shock, treatment-unresponsive ventricular arrhythmia, or congestive heart failure (NYHA class IV) at the time of randomization.\n5. Patients with underlying severe anemia (hemoglobin \\\u003C8 g\u002FdL at baseline) or a transfusion history within four weeks before visit 1.\n6. Patients with underlying severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. The patient is under dialysis or chronic renal failure (creatinine clearance \\\u003C15ml\u002Fmin)\n8. The patient has severe liver disease (variceal bleeding, ascites, hepatic encephalopathy, or jaundice).\n9. The patient has a contraindication to the implantation of an implantable loop recorder (ILR) (such as limited immunocompetence or a wound-healing disorder).\n10. The patient has severe valvular disease (valvular prosthesis, mitral valve repair; rheumatic mitral stenosis is excluded irrespective of the severity of the disease).\n11. The patient has a non-arrhythmic condition necessitating long-term oral anticoagulation.\n12. Hypertrophic cardiomyopathy\n13. The patient is deemed high risk for non-cardioembolic stroke (i.e. significant carotid artery disease).\n14. Patients who are taking warfarin or coumadin.\n15. Patients who are taking dual antiplatelet agents.\n16. Pregnancy, breastfeeding, or women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study. \\*\n\n    \\* Medically acceptable contraceptives include condoms, injectable or implantable contraceptives, intrauterine devices, and oral contraceptives.\n17. Known or suspected malignancy with a history of chemotherapy within 1 year.\n18. The patient has previously implanted cardiac implantable electronic devices or ILR.\n19. Patients with a history of left atrial appendage occlusion or left atrial appendage closure.\n20. The patient is participating in another randomized clinical trial and is under follow-up observation.","89 Years",{"count":578,"type":22},400,[178],"The clinical benefit of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation remains uncertain. We aimed to evaluate the clinical benefit and safety of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation by randomizing into two groups: non-interrupted anticoagulation after the procedure and anticoagulation based on atrial fibrillation recurrence confirmed by implantable loop recorders.",[582],"Atrial Fibrillation",[584,585,586,587,588],"atrial fibrillation","direct oral anticoagulant","catheter ablation","implantable loop recorder","continuous cardiac rhythm monitor",{"date":590,"type":51},"2026-05-04",{"date":592,"type":51},"2024-02-01",{"date":594,"type":22},"2030-12-31",{"name":57,"class":58},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":617,"leadSponsor":619,"locationsCount":59},"100636301","total-neoadjuvant-therapy-with-additional-consolidation-chemotherapy-followed-by-local-excision-versus-total-neoadjuvant-therapy-followed-by-local-excision-at-stage-i-rectal-cancer-100636301","NCT07563907","Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer","Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial","OPTION","Inclusion Criteria:\n\n* Histologically confirmed rectall adenocarcinoma\n* Low rectal cancer (AV \\\u003C 15cm)\n* cT2N0 disease, or pathologic stage T1N0 disease after endoscopic resection with at least one high-risk feature, including: Positive resection margin Lymphovascular invasion Tumor budding ≥5\n* Ability to understand and comply with the requirements of the clinical trial\n\nExclusion Criteria:\n\n* Patients who prefer radical rectal resection\n* Prior history of surgery for rectal cancer\n* Recurrent rectal cancer\n* Synchronous metastatic rectal cancer\n* Evidence of lymph node metastasis or distant metastasis on abdominopelvic CT or chest CT, including para-aortic, common iliac, or external iliac lymph node metastasis\n* Uncontrolled active infection or other uncontrolled medical condition\n* Known hypersensitivity to chemotherapy\n* Patients considered unsuitable for participation in the clinical trial by the principal investigator or study personnel",{"count":605,"type":22},292,[178],"Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial\n\nThe goal of this clinical trial is to find out if adding consolidation chemotherapy with capecitabine after total neoadjuvant chemoradiotherapy (TNT) works to improve oncologic outcomes in patients with stage I rectal cancer. It will also comparethe safety of adding consolidation chemotherapy before local excision.\n\nThe main questions it aims to answer are:\n\n* Does adding consolidation chemotherapy increase the rate of pathologic complete response?\n* What medical problems or side effects do participants have during and after treatment?\n\nResearchers will compare TNT followed by local excision to TNT followed by consolidation chemotherapy with capecitabine and then local excision to see if adding consolidation chemotherapy improves tumor response and treatment outcomes.\n\nParticipants will:\n\n* Receive TNT for stage I rectal cancer\n* Be randomly assigned to one of two treatment groups\n* Undergo local excision after preoperative treatment\n* Visit the clinic for checkups and tests to evaluate tumor response, side effects, recurrence, survival, quality of life, bowel function, urinary function, sexual function, circulating tumor DNA, and treatment-related costs",[609,610,611,612,613],"Organ Preservation","Rectal Cancer Stage I","Total Neoadjuvant Treatment","Consolidation Therapy","Capecitabine","2026-04-26",{"date":590,"type":51},{"date":351,"type":22},{"date":618,"type":22},"2035-12-31",{"name":57,"class":58},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":263,"sex":17,"minAge":363,"maxAge":264,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":640,"locationsCount":59},"100620911","evaluation-of-mixed-reality-cardiopulmonary-resuscitation-training-100620911","NCT07363772","Evaluation of Mixed Reality Cardiopulmonary Resuscitation Training","Evaluation of Efficacy and Effectiveness of Mixed Reality Cardiopulmonary Resuscitation Training","HEROS 4","Inclusion Criteria:\n\n* Adults aged 18-50 years who have not received CPR training within the previous 12 months.\n\nExclusion Criteria:\n\n* Healthcare professionals\n* Individuals unable to safely tolerate MR equipment (e.g. motion sickness)",{"count":629,"type":22},120,[178],"\\\u003CStudy Design\\> This study is a cluster-randomized, stratified, non-inferiority trial designed to evaluate the feasibility, efficacy, and educational effectiveness of HEROS 4.0, a mixed-reality (MR)-based cardiopulmonary resuscitation (CPR) training system, compared with conventional instructor-led CPR training.\n\n\\\u003CObjective \\& Hypothesis\\> The primary objective is to determine whether MR-based HEROS 4.0 CPR training is non-inferior to standard video- and instructor-based CPR training in improving CPR performance quality. The central hypothesis is that participants trained using HEROS 4.0 will achieve comparable CPR quality to those trained using traditional methods, while benefiting from enhanced immersion, scalability, and accessibility.\n\n\\\u003CParticipants\\> A total of 120 adults aged 18-50 years who have not received CPR training within the previous 12 months will be recruited. Participants will be assigned to one of two clusters and randomized in a 1:1 ratio to either the HEROS 4.0 MR training group or the conventional CPR training group.\n\n\\\u003CIntervention \\& Control\\>\n\nParticipants will undergo CPR training according to their assigned group:\n\nIntervention group (HEROS 4.0):\n\nParticipants will receive a two-stage CPR training program consisting of pre-training and on-site MR-based training. As pre-training, participants will be instructed to watch a 40-minute instructional video (conventional CPR training group video) at home prior to their visit. After completing the pre-training, participants will undergo 20 minutes of MR-based CPR training using the HEROS 4.0 system in a dedicated CPR training booth.\n\nControl group (Conventional CPR training):\n\nParticipants will receive 60 minutes of standard CPR education delivered through instructional videos and in-person instructor guidance, reflecting current community CPR training practice.\n\n\\\u003COutcomes\\> Immediately after training, all participants will undergo a standardized cardiac arrest simulation using a CPR quality-measurement manikin. This simulation will assess objective CPR performance metrics as well as subjective outcomes through questionnaires.\n\nTo evaluate knowledge retention and skill durability, all assessments will be repeated 6 months after training using the same simulation scenario and outcome measures.\n\nThe primary outcome is chest compression fraction measured during the standardized simulated cardiac arrest scenario.\n\nSecondary outcomes include quantitative measures of CPR quality and participant-reported outcomes based on survey.",[633,634,635],"Cardiopulmonary Resuscitation (CPR)","Basic Life Support Training Course","Cardiac Arrest (CA)",{"date":560,"type":51},{"date":638,"type":51},"2026-02-01",{"date":379,"type":22},{"name":57,"class":58},""]